Last reviewed · How we verify

NCT06282757

Physiotherapists' Placebo or Nocebo Communication Regarding VR in CMP

Completed NA Last updated 16 September 2025
What this trial tests

NA trial testing Video placebo communication in Communication in 115 participants. Completed in 30 June 2024.

Timeline
1 April 2024
Primary endpoint
30 June 2024
30 June 2024

Quick facts

Lead sponsorHAN University of Applied Sciences
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeother
Enrollment115
Start date1 April 2024
Primary completion30 June 2024
Estimated completion30 June 2024
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

HAN University of Applied Sciences

Who can join

18 and older, any sex, with Communication or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rationale: Chronic musculoskeletal pain (CMP) is a common and disabling condition. Physiotherapy is the most frequently administered non-pharmacological treatment option for patients with CMP and recently virtual reality (VR) was introduced in physiotherapy care as a novel treatment modality. Proper communication about physiotherapy treatment (modalities) is important to improve treatment outcomes, by applying placebo effects enhancing communication and avoiding nocebo effects enhancing communication. However, yet is still unknown to what extent this applies to communication of physiotherapists about VR in patients with CMP. Objective: To determine the effect of physiotherapists' placebo or nocebo therapeutic communication about VR, on treatment credibility and expectation in patients with CMP Study design: Web-based randomized controlled trial. Study population: 100 participants Intervention: The placebo intervention group will be shown an educational video about VR, containing placebo effects enhancing verbal language. The nocebo intervention group will be shown an educational video about VR, containing nocebo effects enhancing verbal language. Primary study parameters: The primary study parameters are treatment credibility and treatment expectation. Treatment credibility and treatment expectations will be measured using the Dutch credibility and expectancy questionnaire (CEQ).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The effect of physiotherapists' explanation of therapeutic virtual reality on treatment expectations in healthy people and people with chronic musculoskeletal pain: Two online RCTs.
    Slatman S, van Lankveld W, Staal JB, van Goor H, et al · · 2026 · PMID 41362581 · DOI 10.1016/j.pecinn.2025.100443

Verify or expand the search:

Other trials of Video nocebo communication

Trials testing the same drug.

Other recruiting trials for Communication

Currently open trials in the same condition.

Other HAN University of Applied Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06282757.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing